AML-109 Preliminary Results of MT-401 in Post-Transplant Measurable Residual Disease Positive (MRD+) Acute Myeloid Leukemia (AML) Patients

Shukaib Arslan,Jingmei Hsu,Betul Oran,Alejandro Sica,Hongtao Liu,Margarida Silverman,Nelli Bejanyan,Antonio DiStasi,Robin McCallum,Silvia Quintero,Gerald Garrett,Karrie Wang,Eric Smith,Tsvetelina Hoang,Tara Shahim,Jeannette Crisostomo,Anna Wilga-Savitski,Jennifer Pickering,Laura Angelo,Anastasiya Smith

Clinical lymphoma myeloma & leukemia/Clinical lymphoma, myeloma and leukemia（2022）

引用 0|浏览10
暂无评分
摘要
The lead-in portion of the ARTEMIS results showed that administration of MT-401 converted MRD+ patients to MRD-indicating that early intervention with MT-401 administration at MRD+ stage in post-transplant AML can be beneficial.
更多
查看译文
关键词
AML,acute myeloid leukemia,multi-tumor-associated antigen-specific T cells,mTAA-specific T cells,measurable residual disease,MRD,Phase II
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要